Jeffrey S.  Glenn, M.D., Ph.D.

Clinical Focus

• Gastroenterology

Administrative Appointments

• Director, Center for Hepatitis and Liver Tissue Engineering , (2006– present )

Honors and Awards

• Summa cum laude, U.C. Berkeley (1984)
• Physician Postdoctoral Fellowship Award, Howard Hughes Medical Institute (1995-1998)
• Career Award, Burroughs Wellcome Fund (1998-2005)
• Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund (2005-2010)
• Elected member, American Society for Clinical Investigation (2008)
• Regents Scholarship, U.C.S.F. (1984-1993)
• Translational Research Award, American Liver Foundation/Amgen/AASLD (1998-2002)

Professional Education

• SUMC - Graduate Medical Education (1999) CA
• SUMC - Graduate Medical Education (1995) CA
• SUMC - Graduate Medical Education (1994) CA
• UCSF School of Medicine (1993) CA
• Ph.D., U.C.S.F. Biochemistry and Biophysics (1992)
• M.D., U.C.S.F. Medicine/MSTP (1993)

Postdoctoral Advisees

• Nam-Joon Cho, Hadas Dvory-Sobol, Choongho Lee, James Lue, Phillip Pang

Graduate & Fellowship Program Affiliations

• Medicine
• Microbiology and Immunology
• Infectious Diseases
• Pediatrics

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. 

• Consulting: Eiger BioPharmaceuticals, Epiphany, Presidio Pharmaceuticals, Romark Laboratories
• Equity: Eiger BioPharmaceuticals, Epiphany, Presidio Pharmaceuticals, Romark Laboratories
• Service on Board of Directors: Eiger BioPharmaceuticals

Research Interests

Dr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Current projects aim to better understand the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses-both as a mechanism of intracellular trafficking and trigger of virus assembly, and as a target for a promising antiviral treatment. The function and cell biology of the hepatitis C virus (HCV) non-structural proteins are also being studied. Here the focus is on identifying key determinants of pathogenesis and designing novel antiviral strategies. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.

Publications

• Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. Cho NJ,  Elazar M, Xiong A, Lee W, Chiao E, Baker J, Frank CW, Glenn JS.  Biomed Mater.  2009; 4 (1): 11001
• The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Elazar M,  Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS.  Gastroenterology.  2009; 137 (5): 1827-35
• Alpha-helical peptide-induced vesicle rupture revealing new insight into the vesicle fusion process as monitored in situ by quartz crystal microbalance-dissipation and reflectometry. Cho NJ,  Wang G, Edvardsson M, Glenn JS, Hook F, Frank CW.  Anal Chem.  2009; 81 (12): 4752-61
• The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. Pang PS,  Planet PJ, Glenn JS.  PLoS One.  2009; 4 (8): e6579
• The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Pang PS,  Kamal A, Glenn JS.  Liver Transpl.  2009; 15 (9): 1126-32
• The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Einav S,  Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS.  Hepatology.  2008; 47 (3): 827-35
• Isolation of Human Fetal Liver Progenitors and Their Enhanced Proliferation by Three-Dimensional Coculture with Endothelial Cells. Xiong A,  Austin TW, Lagasse E, Uchida N, Tamaki S, Bordier BB, Weissman IL, Glenn JS, Millan MT.  Tissue Eng Part A.  2008;
• Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells. Chiao E,  Elazar M, Xing Y, Xiong A, Kmet M, Millan MT, Glenn JS, Wong WH, Baker J.  Stem Cells.  2008; 26 (8): 2032-41
• Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Korba BE,  Elazar M, Lui P, Rossignol JF, Glenn JS.  Antimicrob Agents Chemother.  2008; 52 (11): 4069-71
• Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells. Xiong A,  Austin TW, Lagasse E, Uchida N, Tamaki S, Bordier BB, Weissman IL, Glenn JS, Millan MT.  Tissue Eng Part A.  2008; 14 (6): 995-1006
• Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Einav S,  Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR.  Nat Biotechnol.  2008; 26 (9): 1019-27
• The Power of silence: application of small interfering RNAs to gastrointestinal diseases. Sklan EH,  Glenn JS.  Gastroenterology.  2007; 132 (7): 2291-5
• Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes. Cho NJ,  Cheong KH, Lee C, Frank CW, Glenn JS.  J Virol.  2007; 81 (12): 6682-9
• Hepatitis d. Koytak ES,  Yurdaydin C, Glenn JS.  Curr Treat Options Gastroenterol.  2007; 10 (6): 456-63
• TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. Sklan EH,  Serrano RL, Einav S, Pfeffer SR, Lambright DG, Glenn JS.  J Biol Chem.  2007; 282 (50): 36354-61
• Creation of lipid partitions by deposition of amphipathic viral peptides. Cho NJ,  Cho SJ, Hardesty JO, Glenn JS, Frank CW.  Langmuir.  2007; 23 (21): 10855-63
• Employing two different quartz crystal microbalance models to study changes in viscoelastic behavior upon transformation of lipid vesicles to a bilayer on a gold surface. Cho NJ,  Kanazawa KK, Glenn JS, Frank CW.  Anal Chem.  2007; 79 (18): 7027-35
• A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. Sklan EH,  Staschke K, Oakes TM, Elazar M, Winters M, Aroeti B, Danieli T, Glenn JS.  J Virol.  2007; 81 (20): 11096-105
• Employing an amphipathic viral peptide to create a lipid bilayer on Au and TiO2. Cho NJ,  Cho SJ, Cheong KH, Glenn JS, Frank CW.  J Am Chem Soc.  2007; 129 (33): 10050-1
• Molecular virology of the hepatitis C virus: implication for novel therapies. Glenn JS,  Infect Dis Clin North Am.  2006; 20 (1): 81-98
• Prenylation of HDAg and antiviral drug development. Glenn JS,  Curr Top Microbiol Immunol.  2006; 307 133-49
• Novel therapies for hepatitis C virus based on lessons from virology. Glenn JS,  Clin Gastroenterol Hepatol.  2005; 3 (10 Suppl 2): S86-8
• Molecular virology of the hepatitis C virus: implication for novel therapies. Glenn JS,  Clin Liver Dis.  2005; 9 (3): 353-69, v
• Overdependence on the host-an Achilles' heel of HCV? Glenn JS,  Hepatology.  2004; 39 (6): 1734-5
• Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors. Bordier BB,  Glenn JS.  Methods Mol Med.  2004; 96 539-53
• Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. Matto M,  Rice CM, Aroeti B, Glenn JS.  J Virol.  2004; 78 (21): 12047-53
• An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. Elazar M,  Liu P, Rice CM, Glenn JS.  J Virol.  2004; 78 (20): 11393-400
• A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. Einav S,  Elazar M, Danieli T, Glenn JS.  J Virol.  2004; 78 (20): 11288-95
• In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. Bordier BB,  Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS.  J Clin Invest.  2003; 112 (3): 407-14
• Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. Elazar M,  Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS.  J Virol.  2003; 77 (10): 6055-61
• Prenylation inhibitors: a novel class of antiviral agents. Einav S,  Glenn JS.  J Antimicrob Chemother.  2003; 52 (6): 883-6
• A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. Bordier BB,  Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, Glenn JS.  J Virol.  2002; 76 (20): 10465-72
• Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Ohashi K,  Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA.  Nat Med.  2000; 6 (3): 327-31
• Shutting the door on hepatitis delta virus (HDV): Sensitivity to prenylation inhibition prompts new therapeutic strategy Glenn JS,  Viral Hepatitis Reviews.  1999; 53 13-26
• Use of a prenylation inhibitor as a novel antiviral agent. Glenn JS,  Marsters JC, Greenberg HB.  J Virol.  1998; 72 (11): 9303-6
• Finding the iron in the melting pot--practical use of a new genetic assay for hereditary hemochromatosis. Glenn JS,  Cheung RC.  West J Med.  1998; 168 (6): 525-7
• Identification of a prenylation site in delta virus large antigen. Glenn JS,  Watson JA, Havel CM, White JM.  Science.  1992; 256 (5061): 1331-3